Julie F. M. Geerts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julie F. M. Geerts has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
A M J van Nistelrooij
Department of Surgery, Erasmus MC - University Medical Center , Dr. Molewaterplein 40, 3015 GD, Rotterdam
1 shared publicationB P L Wijnhoven
Department of Surgery, Erasmus MC - University Medical Center , Dr. Molewaterplein 40, 3015 GD, Rotterdam
1 shared publicationBas P. L. Wijnhoven
Department of Surgery Erasmus Medical Centre Rotterdam The Netherlands
1 shared publication- Bas P. L. Wijnhoven
Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
1 shared publication - Bastiaan Rijk Klarenbeek
Department of Surgery, Radboud University Medical Center , Nijmegen
1 shared publication Bianca Mostert
Department of Medical Oncology Erasmus Medical Centre Rotterdam the Netherlands
1 shared publication
Latest Publications
- 2 July 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (4)
Reasons for hospital readmissions after esophagectomy for cancer
Summary: While postoperative complications are established predictors of readmission after esophagectomy, reasons for readmission are still elusive, specifically in patients without complications during the index admission. This study assessed reasons for readmission and explored potential predictors in this lower-risk subgroup. A retrospective multicenter cohort study included all patients ≥18 years who underwent curative esophagectomy between 2020 and 2023 across three Dutch hospitals. Patients with in-hospital mortality or missing readmission data were excluded. The primary outcome was the reason for 30-day readmission. Secondary outcome was the identification of risk factors for readmission using uni- and multivariable logistic regression. Of 663 patients, 350 (52.8%) had an uncomplicated index admission, with a 30-day readmission rate of 12.6% (44/350). The most common causes for readmission were anastomotic leakage (32.6%), pulmonary complications (20.9%), insufficient intake (14.0%), and infections (14.0%). No significant associations were found with age, sex, the American Society of Anesthesiologists (ASA) classification, Charlson Comorbidity Index, tube feeding, length of stay, or surgical approach. Among patients readmitted with anastomotic leakage, 11/14 had met functional recovery criteria at discharge. Three patients had unexplained subtle increases in C-reactive protein (CRP) or leukocyte count. Three patients underwent a computed tomography (CT) scan during the index admission. Readmission remains common, even in patients with an initially uneventful recovery, and is frequently caused by undetected or delayed complications including anastomotic leakage. Traditional predictors did not identify patients at risk for readmission in this cohort. Subtle deviations before discharge may represent early warning signs and require validation in future prospective research.
- 2 July 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (4)
Reasons for hospital readmissions after esophagectomy for cancer
Summary: While postoperative complications are established predictors of readmission after esophagectomy, reasons for readmission are still elusive, specifically in patients without complications during the index admission. This study assessed reasons for readmission and explored potential predictors in this lower-risk subgroup. A retrospective multicenter cohort study included all patients ≥18 years who underwent curative esophagectomy between 2020 and 2023 across three Dutch hospitals. Patients with in-hospital mortality or missing readmission data were excluded. The primary outcome was the reason for 30-day readmission. Secondary outcome was the identification of risk factors for readmission using uni- and multivariable logistic regression. Of 663 patients, 350 (52.8%) had an uncomplicated index admission, with a 30-day readmission rate of 12.6% (44/350). The most common causes for readmission were anastomotic leakage (32.6%), pulmonary complications (20.9%), insufficient intake (14.0%), and infections (14.0%). No significant associations were found with age, sex, the American Society of Anesthesiologists (ASA) classification, Charlson Comorbidity Index, tube feeding, length of stay, or surgical approach. Among patients readmitted with anastomotic leakage, 11/14 had met functional recovery criteria at discharge. Three patients had unexplained subtle increases in C-reactive protein (CRP) or leukocyte count. Three patients underwent a computed tomography (CT) scan during the index admission. Readmission remains common, even in patients with an initially uneventful recovery, and is frequently caused by undetected or delayed complications including anastomotic leakage. Traditional predictors did not identify patients at risk for readmission in this cohort. Subtle deviations before discharge may represent early warning signs and require validation in future prospective research.
- Open Access
- 5 June 2025
- Published by Wiley in International Journal of Cancer
- Vol. 157 (7) , 1446-1457
Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: A nationwide population‐based study in the Netherlands
Care for metastatic esophageal (EC) or gastric cancer (GC) includes a large variety of treatment modalities. Data on treatment variation across centers are unknown. This study investigated treatment variation across hospitals and its effect on overall survival (OS) in the Netherlands by conducting a nationwide retrospective cohort study with population‐based data from the Netherlands Cancer Registry. Patients diagnosed with synchronous metastatic EC/GC between 2015 and 2022 were included. Multilevel logistic regression assessed treatment patterns according to hospital of diagnosis. OS was analyzed using Cox regression analysis after categorizing hospitals into tertiles based on their adjusted odds (low/medium/high) for systemic treatment (chemotherapy, targeted therapy, and immunotherapy). Among 8406 EC and 3871 GC patients, the proportion receiving systemic treatment varied substantially: 19.8%–69.6% for EC and 15.8%–81.3% for GC across hospitals. Hospital of diagnosis was significantly associated with the adjusted probability of receiving systemic treatment (p < .0001). Ten out of 78 EC (12.8%) and 7 out of 73 (9.6%) GC hospitals had significantly lower systemic treatment probabilities. EC patients with OS ≥4 months diagnosed at hospitals with lower probabilities had significantly worse OS compared to high‐probability hospitals (hazard ratios [HR] 0.87 [0.79–0.95] p = .002). GC patients from low‐probability hospitals had significantly worse OS than from medium‐ (HR 0.86 [0.76–0.96], p = .011) or high‐probability hospitals (HR 0.73 [0.64–0.82], p < .0001). In conclusion, this study showed substantial hospital variation in treatment for metastatic EC and GC. Hospital of diagnosis was not only associated with the probability of receiving systemic treatment but also OS. This reflects the challenge of ensuring equal healthcare access.
- 5 June 2025
- Published by Wiley in International Journal of Cancer
- Vol. 157 (7) , 1446-1457
Open AccessHospital variation in treatment for synchronous metastatic esophageal and gastric cancer: A nationwide population‐based study in the Netherlands
Care for metastatic esophageal (EC) or gastric cancer (GC) includes a large variety of treatment modalities. Data on treatment variation across centers are unknown. This study investigated treatment variation across hospitals and its effect on overall survival (OS) in the Netherlands by conducting a nationwide retrospective cohort study with population‐based data from the Netherlands Cancer Registry. Patients diagnosed with synchronous metastatic EC/GC between 2015 and 2022 were included. Multilevel logistic regression assessed treatment patterns according to hospital of diagnosis. OS was analyzed using Cox regression analysis after categorizing hospitals into tertiles based on their adjusted odds (low/medium/high) for systemic treatment (chemotherapy, targeted therapy, and immunotherapy). Among 8406 EC and 3871 GC patients, the proportion receiving systemic treatment varied substantially: 19.8%–69.6% for EC and 15.8%–81.3% for GC across hospitals. Hospital of diagnosis was significantly associated with the adjusted probability of receiving systemic treatment (p < .0001). Ten out of 78 EC (12.8%) and 7 out of 73 (9.6%) GC hospitals had significantly lower systemic treatment probabilities. EC patients with OS ≥4 months diagnosed at hospitals with lower probabilities had significantly worse OS compared to high‐probability hospitals (hazard ratios [HR] 0.87 [0.79–0.95] p = .002). GC patients from low‐probability hospitals had significantly worse OS than from medium‐ (HR 0.86 [0.76–0.96], p = .011) or high‐probability hospitals (HR 0.73 [0.64–0.82], p < .0001). In conclusion, this study showed substantial hospital variation in treatment for metastatic EC and GC. Hospital of diagnosis was not only associated with the probability of receiving systemic treatment but also OS. This reflects the challenge of ensuring equal healthcare access.
- 16 November 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (1)
Risk factors for readmission following esophagectomy and gastrectomy for cancer
Hospital readmission after surgery is a key quality indicator. This nationwide cohort study aimed to assess readmission rates following esophagectomy and gastrectomy for cancer and identify associated risk factors. Data were extracted from the Dutch Upper GI Cancer Audit (DUCA) for patients with esophagogastric cancer who underwent esophagectomy or gastrectomy with curative intent between January 2011 and June 2016. Logistic regression analysis identified risk factors for 30-day readmission. In total, 5566 patients were included. Readmission within 30 days occurred in 483 of 3488 (13.8%) patients after esophagectomy and 243 of 2078 patients (11.7%) after gastrectomy. Both minor (Clavien Dindo 1–2) and major (Clavien Dindo ≥3) postoperative complications were independent predictors of readmission after esophagectomy (OR 2.99; 95%CI 2.23–4.02; p < 0.001 and OR 5.20; 95%CI 3.82–7.09; p < 0.001). Specific complications included pulmonary (OR 1.49; 95%CI 1.20–1.85; p < 0.001), gastrointestinal (OR 2.43; 95%CI 1.94–3.05; p < 0.001), and infectious (OR 2.27; 95%CI 1.60–3.22; p < 0.001). Prolonged length of stay (pLOS) was associated with higher readmission rates in patients without complications following esophagectomy (OR 1.91 95% CI 1.19–3.07; p = 0.008), but lower rates in those with complications (OR 0.65 95% CI 0.51–0.83; p < 0.001). For gastrectomy, postoperative complications were also linked to readmission (OR 3.18; 95%CI 2.30–4.40; p < 0.001), particularly gastrointestinal (OR 2.16; 95%CI 1.40–3.32; p < 0.001), and infectious (OR 3.80; 95%CI 2.53–5.71; p < 0.001). Readmission after esophagogastric resection is common, particularly among patients with both minor and major postoperative complications. Prolonged stay after esophagectomy impacts readmission risk differently based on the presence of complications.
- 16 November 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (1)
Risk factors for readmission following esophagectomy and gastrectomy for cancer
Hospital readmission after surgery is a key quality indicator. This nationwide cohort study aimed to assess readmission rates following esophagectomy and gastrectomy for cancer and identify associated risk factors. Data were extracted from the Dutch Upper GI Cancer Audit (DUCA) for patients with esophagogastric cancer who underwent esophagectomy or gastrectomy with curative intent between January 2011 and June 2016. Logistic regression analysis identified risk factors for 30-day readmission. In total, 5566 patients were included. Readmission within 30 days occurred in 483 of 3488 (13.8%) patients after esophagectomy and 243 of 2078 patients (11.7%) after gastrectomy. Both minor (Clavien Dindo 1–2) and major (Clavien Dindo ≥3) postoperative complications were independent predictors of readmission after esophagectomy (OR 2.99; 95%CI 2.23–4.02; p < 0.001 and OR 5.20; 95%CI 3.82–7.09; p < 0.001). Specific complications included pulmonary (OR 1.49; 95%CI 1.20–1.85; p < 0.001), gastrointestinal (OR 2.43; 95%CI 1.94–3.05; p < 0.001), and infectious (OR 2.27; 95%CI 1.60–3.22; p < 0.001). Prolonged length of stay (pLOS) was associated with higher readmission rates in patients without complications following esophagectomy (OR 1.91 95% CI 1.19–3.07; p = 0.008), but lower rates in those with complications (OR 0.65 95% CI 0.51–0.83; p < 0.001). For gastrectomy, postoperative complications were also linked to readmission (OR 3.18; 95%CI 2.30–4.40; p < 0.001), particularly gastrointestinal (OR 2.16; 95%CI 1.40–3.32; p < 0.001), and infectious (OR 3.80; 95%CI 2.53–5.71; p < 0.001). Readmission after esophagogastric resection is common, particularly among patients with both minor and major postoperative complications. Prolonged stay after esophagectomy impacts readmission risk differently based on the presence of complications.